化学発光免疫測定法市場:製品別(装置、消耗品)、技術別(化学発光酵素、微粒子化学発光)、サンプル別(血液、尿)、用途別(感染症、癌)、エンドユーザー別 - 2028年までの世界予測Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028 化学発光イムノアッセイ市場は、2023年に推定132億米ドルと評価され、予測期間中のCAGRは7.5%で2028年には190億米ドルに達すると予測されている。HIV/AIDS、肝炎、呼吸器感染症、性感染症などの疾患は、効果的な... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー化学発光イムノアッセイ市場は、2023年に推定132億米ドルと評価され、予測期間中のCAGRは7.5%で2028年には190億米ドルに達すると予測されている。HIV/AIDS、肝炎、呼吸器感染症、性感染症などの疾患は、効果的な治療と管理のために正確でタイムリーな診断を必要とする。ケミルミネッセンスイムノアッセイは、こうした感染症の診断やモニタリングに大きな役割を果たしており、この分野の市場成長を牽引している。"予測期間中、化学発光イムノアッセイ市場のサンプルタイプ別では、血液サンプル分野が最も高い成長率を示すと予測される" 化学発光イムノアッセイ市場は、血液、尿、唾液、その他のサンプルタイプに区分される。ケミルミネッセンスイムノアッセイにおける血液セグメントは、主に献血数の増加によって大きな成長を遂げており、慢性疾患や感染症の罹患率の上昇も血液サンプルセグメントの成長を支えている。WHOによると、2020年には世界中で1億1850万件以上の献血が行われた。WHOは、献血されたすべての血液について、使用前に感染症、特に梅毒、HIV、マラリア、HBV、B型肝炎、C型肝炎の検査を行うことを推奨している。 "予測期間中、化学発光イムノアッセイ市場のアプリケーション別では、腫瘍学検査分野が最も高い成長率を記録すると予測される" 世界の化学発光免疫測定市場は、感染症、内分泌、腫瘍、骨・ミネラル障害、循環器、血液スクリーニング、自己免疫疾患、アレルギー診断、毒物学、新生児スクリーニング、治療薬モニタリング、呼吸器、神経、代謝障害、消化器、その他の用途に二分される。化学発光イムノアッセイ市場では、腫瘍学検査分野が最も高い成長率を示すと予想されている。癌検査に対する需要の急増は、癌の発生率の上昇、癌の早期発見と早期治療の必要性の強調の増加、癌検診対策の強化といった様々な要因によるものである。 「アジア太平洋:最も急成長している地域の化学発光免疫測定法市場" 世界の化学発光免疫測定市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分される。アジア太平洋地域は予測期間中に最も高いCAGRを記録すると予測されている。中国やインドなどのアジア太平洋地域の新興国は、大規模な対象人口の存在と相まって、医療インフラの整備に投資している。これらの要因は、この地域で事業を展開する化学発光免疫測定企業に大きな成長機会をもたらすと期待されている。 化学発光イムノアッセイ市場における主要参入企業のプロファイルの内訳: - 企業タイプ別:ティア1:28%、ティア2:41%、ティア3:31 - 役職別Cレベル:30%、Dレベル:34%、その他:36 - 地域別北米:37%、欧州:28%、アジア太平洋地域:20%、その他の地域:15 この市場の主要プレーヤーは、F.ホフマン・ラ・ロシュ社(スイス)、ダナハー社(スイス)である。(スイス)、Danaher Corporation(米国)、Siemens Healthineers AG(ドイツ)、DiaSorin S.p.A.(イタリア)、Abbott Laboratories(米国)、Shenzhen Mindray Bio-medical Electronics Co.(Ltd.(中国)、シスメックス株式会社(日本)、Diatron(ハンガリー)、Getein Biotech, Inc.(中国)、Werfen(スペイン)、QuidelOrtho Corporation(米国)、EUROIMMUN(ドイツ)、Merck KGaA(ドイツ)、東ソー株式会社(日本)、Trivitron Healthcare(インド)、Abnova Corporation(台湾)、Elabscience(米国)、Maccura Biotechnology Co.(Ltd.(中国)、Autobio Diagnostics Co.(Ltd.(中国)、Jiangsu Zecen Biotech Co., Ltd.(中国)、Rayto Life and Analytical Sciences Co.(中国)、Daan Gene Co.(中国)、DYNEX TECHNOLOGIES, Inc.(米国)、Zybio, Inc.(中国)、Wiener Laboratorios SAIC(アルゼンチン)、Tianjin Era Biology Technology Co.(Ltd.(中国)。 調査範囲 この調査レポートは、化学発光免疫測定法市場を製品別(消耗品、機器)、技術別(化学発光酵素技術(CLEIA)、電気化学発光免疫測定法(ECLI)、微粒子化学発光免疫測定法)、サンプルタイプ別(血液、尿、唾液、その他のサンプルタイプ)、用途別(感染症、内分泌学、腫瘍学、骨・ミネラル疾患、循環器学、血液スクリーニング、自己免疫疾患、アレルギー診断、毒物学、新生児スクリーニング、治療薬モニタリング、呼吸器学、神経学、代謝異常、消化器学、その他のアプリケーション)、エンドユーザー(病院、臨床検査室、製薬・バイオテクノロジー企業、受託研究機関、その他のエンドユーザー)、地域(北米、欧州、アジア太平洋地域、その他の地域)。本レポートでは、化学発光イムノアッセイ市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、買収、契約、新製品の発売と承認、化学発光免疫測定法市場に関連する最近の動向に関する洞察を提供しています。化学発光イムノアッセイ市場のエコシステムにおける今後の新興企業の競争分析も本レポートでカバーしています。 このレポートを購入する理由 本レポートは、化学発光イムノアッセイ市場全体およびサブセグメントの収益数の最も近い近似値に関する情報を提供することで、同市場の市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。 本レポートでは、以下のポイントに関する洞察を提供しています: - 主要推進要因の分析(慢性疾患および感染症の増加、CLIA技術向上の進歩、ポイントオブケア検査(POCT)需要の高まり、バイオテクノロジーおよびバイオ医薬品産業の成長、高齢者人口の増加、個別化医療へのシフト)、化学発光免疫測定法市場の成長に影響を与える阻害要因(CLIAシステムおよび試薬の高コスト、交差反応性および干渉)、機会(新興国における高成長の見込み、共同研究およびパートナーシップ)、課題(不利な償還シナリオ、熟練専門家の不足)。 - 製品開発/イノベーション:化学発光免疫測定法市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。 - 市場開発:有利な市場に関する包括的情報 - 当レポートでは、様々な地域における化学発光免疫測定法市場を分析しています。 - 市場の多様化:化学発光免疫測定法市場における新製品&サービス、未開拓の地域、最近の開発、投資に関する詳細な情報 - 競合評価:F.ホフマン・ラ・ロシュ社(スイス)、ダナハー社(スイス)など主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。(スイス)、Danaher Corporation (米国)、Seimens Healthineers AG (ドイツ)、Abbott Laboratories (米国)、DiaSorin S.p.A.(イタリア)などの化学発光免疫測定市場戦略における主要企業の市場シェア、成長戦略、サービス提供などを詳細に評価。 目次1 INTRODUCTION 311.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 31 1.2.1 INCLUSIONS AND EXCLUSIONS 32 1.3 MARKET SCOPE 33 1.3.1 MARKETS COVERED 33 FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION 33 1.3.2 GEOGRAPHICAL SCOPE 33 1.3.3 YEARS CONSIDERED 34 1.4 CURRENCY CONSIDERED 34 1.5 STAKEHOLDERS 35 2 RESEARCH METHODOLOGY 36 2.1 RESEARCH APPROACH 36 FIGURE 2 RESEARCH DESIGN 36 2.1.1 SECONDARY DATA 37 2.1.1.1 Key data from secondary sources 38 2.1.2 PRIMARY DATA 38 2.1.2.1 Primary sources 39 2.1.2.2 Key data from primary sources 40 2.1.2.3 Key industry insights 41 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS 41 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 42 2.2 MARKET SIZE ESTIMATION 42 FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION 43 FIGURE 6 MARKET ESTIMATION FROM IVD MARKET 44 FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET 44 FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 45 FIGURE 9 TOP-DOWN APPROACH 45 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 47 FIGURE 10 DATA TRIANGULATION METHODOLOGY 47 2.4 MARKET SHARE ANALYSIS 48 2.5 STUDY ASSUMPTIONS 48 2.6 RESEARCH LIMITATIONS 48 2.7 RISK ASSESSMENT 49 TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET 49 2.8 GROWTH RATE ASSUMPTIONS 49 2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 49 3 EXECUTIVE SUMMARY 51 FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION) 51 FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 52 FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION) 53 FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION) 54 FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 55 FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 56 4 PREMIUM INSIGHTS 57 4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW 57 FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 57 4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022) 58 FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58 4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 59 FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 59 4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX 60 FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD 60 4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS 61 FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD 61 5 MARKET OVERVIEW 62 5.1 INTRODUCTION 62 5.2 MARKET DYNAMICS 62 FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62 5.2.1 DRIVERS 63 5.2.1.1 Increasing incidences of chronic and infectious diseases globally 63 FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL) 63 FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS) 64 5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years 64 5.2.1.3 Growth of biotechnology and biopharmaceutical industries 66 5.2.1.4 Rapid increase in geriatric population globally 67 FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 67 5.2.1.5 Shift toward personalized medicines and individualized treatment decisions 68 5.2.2 RESTRAINTS 68 5.2.2.1 High cost of chemiluminescence systems and reagents 68 5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference 68 5.2.3 OPPORTUNITIES 69 5.2.3.1 High growth prospects for players in emerging economies 69 5.2.3.2 Increasing number of collaborations and partnerships 70 5.2.4 CHALLENGES 70 5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems 70 5.2.4.2 Lack of skilled professionals and aging workforce 70 5.3 VALUE CHAIN ANALYSIS 71 FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 71 5.4 SUPPLY CHAIN ANALYSIS 72 FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES 72 5.5 PORTER’S FIVE FORCES ANALYSIS 73 TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS 73 5.5.1 DEGREE OF COMPETITION 73 5.5.2 BARGAINING POWER OF SUPPLIERS 73 5.5.3 BARGAINING POWER OF BUYERS 73 5.5.4 THREAT OF SUBSTITUTES 73 5.5.5 THREAT OF NEW ENTRANTS 74 5.6 KEY STAKEHOLDERS AND BUYING CRITERIA 74 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 74 FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 74 TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 74 5.6.2 BUYING CRITERIA 75 FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS 75 TABLE 4 KEY BUYING CRITERIA, BY END USER 75 5.7 REGULATORY LANDSCAPE 76 5.7.1 US 76 TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 76 FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES 77 5.7.2 CANADA 78 FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES 78 5.7.3 EUROPE 78 TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES 78 5.7.4 JAPAN 79 FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 79 TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS 80 TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80 5.7.5 CHINA 80 TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80 5.7.6 INDIA 81 FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES 81 5.7.7 INDONESIA 81 TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 82 5.7.8 RUSSIA 82 TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES 82 5.7.9 SAUDI ARABIA 83 TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83 5.7.10 MEXICO 83 FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 83 TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84 5.7.11 BRAZIL 84 FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 85 5.7.12 SOUTH KOREA 85 TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85 5.7.13 MIDDLE EAST 85 5.7.14 AFRICA 86 5.8 TECHNOLOGY ANALYSIS 86 TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 86 5.9 TRADE ANALYSIS 87 5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS 87 TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 87 TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 87 5.10 ECOSYSTEM MAPPING 88 FIGURE 36 ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 88 5.10.1 ROLE IN ECOSYSTEM 88 5.10.2 KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 89 5.11 PATENT ANALYSIS 89 5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 90 TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024 90 5.13 PRICING ANALYSIS 91 5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS) 91 TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD) 91 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91 6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT 92 6.1 INTRODUCTION 93 TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 93 6.2 CONSUMABLES 93 6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD 93 TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE 94 TABLE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 95 6.3 INSTRUMENTS 95 6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET 95 TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE 96 TABLE 24 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 97 7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY 98 7.1 INTRODUCTION 99 TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 99 7.2 CHEMILUMINESCENCE ENZYME 99 7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET 99 TABLE 26 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION) 100 7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY 100 7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET 100 TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION) 101 7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY 101 7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET 101 TABLE 28 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION) 102 8 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE 103 8.1 INTRODUCTION 104 TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 104 8.2 BLOOD 104 8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET 104 TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION) 105 8.3 URINE 105 8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET 105 TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION) 106 8.4 SALIVA 106 8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET 106 TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION) 107 8.5 OTHER SAMPLE TYPES 107 TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION) 108 9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION 109 9.1 INTRODUCTION 110 TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110 9.2 INFECTIOUS DISEASES 111 9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET 111 TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 111 9.3 ENDOCRINOLOGY 112 9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET 112 TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 112 9.4 ONCOLOGY 113 9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET 113 TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 114 TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 114 9.5 CARDIOLOGY 115 9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET 115 TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION) 115 9.6 ALLERGY DIAGNOSTICS 116 9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS 116 TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 116 9.7 BLOOD SCREENING 117 9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET 117 TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION) 117 9.8 AUTOIMMUNE DISORDERS 118 9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET 118 TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION) 119 9.9 BONE & MINERAL DISORDERS 119 9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 119 TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 120 9.10 TOXICOLOGY 120 9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 120 TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION) 121 9.11 NEWBORN SCREENING 121 9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL 121 TABLE 45 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION) 122 9.12 THERAPEUTIC DRUG MONITORING 122 9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET 122 TABLE 46 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION) 123 9.13 METABOLIC DISORDERS 123 9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 123 FIGURE 37 GLOBAL INCIDENCE OF DIABETES 124 TABLE 47 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 124 9.14 GASTROENTEROLOGY 125 9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET 125 TABLE 48 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION) 125 9.15 NEUROLOGY 126 9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT 126 TABLE 49 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 126 9.16 RESPIRATORY 127 9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET 127 TABLE 50 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION) 127 9.17 OTHER APPLICATIONS 128 TABLE 51 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 128 10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER 129 10.1 INTRODUCTION 130 TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 130 10.2 HOSPITALS 130 10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET 130 TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 132 10.3 CLINICAL LABORATORIES 132 10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT 132 TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 133 10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 134 10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET 134 TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 135 10.5 OTHER END USERS 135 TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 136 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION 137 11.1 INTRODUCTION 138 TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 138 11.2 NORTH AMERICA 139 FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 140 TABLE 58 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141 TABLE 59 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141 TABLE 60 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 142 TABLE 61 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 142 TABLE 62 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143 TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 144 11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA 144 11.2.2 US 145 11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period 145 TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 145 TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146 TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 146 TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147 TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 148 11.2.3 CANADA 148 11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market 148 TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES 148 TABLE 70 CANADA: MACROECONOMIC INDICATORS 150 TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150 TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 151 TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 151 TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152 TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 153 11.3 EUROPE 153 TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154 TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154 TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155 TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 155 TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 156 TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 157 11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE 157 11.3.2 GERMANY 157 11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market 157 TABLE 82 GERMANY: MACROECONOMIC INDICATORS 158 TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159 TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 159 TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 160 TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161 TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 162 11.3.3 FRANCE 162 11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market 162 TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163 TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163 TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 164 TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165 TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 166 11.3.4 UK 166 11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market 166 TABLE 93 UK: MACROECONOMIC INDICATORS 167 TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 168 TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 168 TABLE 96 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 169 TABLE 97 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170 TABLE 98 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 171 11.3.5 ITALY 171 11.3.5.1 Growing geriatric population and increasing support for research to drive market 171 TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172 TABLE 100 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172 TABLE 101 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 173 TABLE 102 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174 TABLE 103 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 175 11.3.6 SPAIN 175 11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market 175 TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176 TABLE 105 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 176 TABLE 106 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 177 TABLE 107 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178 TABLE 108 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 179 11.3.7 REST OF EUROPE 179 TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 180 TABLE 110 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180 TABLE 111 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 181 TABLE 112 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182 TABLE 113 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 183 11.4 ASIA PACIFIC 183 FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 184 TABLE 114 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 185 TABLE 115 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 185 TABLE 116 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186 TABLE 117 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 186 TABLE 118 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187 TABLE 119 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 188 11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC 188 11.4.2 JAPAN 188 11.4.2.1 Growing investments in clinical diagnostics research to drive market 188 TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 189 TABLE 121 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 190 TABLE 122 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 190 TABLE 123 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191 TABLE 124 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 192 11.4.3 CHINA 192 11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period 192 TABLE 125 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 193 TABLE 126 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 194 TABLE 127 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 194 TABLE 128 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195 TABLE 129 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 196 11.4.4 INDIA 196 11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market 196 TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 197 TABLE 131 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 198 TABLE 132 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 198 TABLE 133 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 199 TABLE 134 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 200 11.4.5 SOUTH KOREA 200 11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market 200 TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 201 TABLE 136 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 201 TABLE 137 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 202 TABLE 138 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203 TABLE 139 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 204 11.4.6 REST OF ASIA PACIFIC 204 TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205 TABLE 141 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 206 TABLE 142 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 206 TABLE 143 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207 TABLE 144 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 208 11.5 REST OF THE WORLD 208 TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 208 TABLE 146 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 209 TABLE 147 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 209 TABLE 148 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 210 TABLE 149 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211 TABLE 150 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 212 11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD 212 11.5.2 LATIN AMERICA 212 11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market 212 TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 213 TABLE 152 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 214 TABLE 153 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 214 TABLE 154 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 215 TABLE 155 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 216 11.5.3 MIDDLE EAST & AFRICA 216 11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market 216 TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 217 TABLE 157 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 217 TABLE 158 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 218 TABLE 159 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 219 TABLE 160 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 220 12 COMPETITIVE LANDSCAPE 221 12.1 OVERVIEW 221 12.2 STRATEGIES ADOPTED BY KEY PLAYERS 221 TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS 222 12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 223 FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 223 12.4 MARKET SHARE ANALYSIS 224 TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION 224 FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022) 225 12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 226 12.5.1 STARS 226 12.5.2 EMERGING LEADERS 226 12.5.3 PERVASIVE PLAYERS 226 12.5.4 PARTICIPANTS 226 FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS 227 12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 228 12.6.1 PROGRESSIVE COMPANIES 228 12.6.2 STARTING BLOCKS 228 12.6.3 RESPONSIVE COMPANIES 228 12.6.4 DYNAMIC COMPANIES 228 FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES 229 12.7 COMPETITIVE BENCHMARKING 230 TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES 230 12.8 COMPANY FOOTPRINT ANALYSIS 231 TABLE 164 OVERALL COMPANY FOOTPRINT 231 TABLE 165 COMPANY PRODUCT FOOTPRINT 231 TABLE 166 COMPANY REGIONAL FOOTPRINT 232 12.9 COMPETITIVE SCENARIO 232 12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS 232 TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023 232 12.9.2 KEY DEALS 234 TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020–2023 234 12.9.3 OTHER KEY DEVELOPMENTS 234 TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023 234 13 COMPANY PROFILES 236 13.1 KEY PLAYERS 236 (Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)* 13.1.1 F. HOFFMANN-LA ROCHE LTD. 236 TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 236 FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 237 13.1.2 DANAHER CORPORATION 239 TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW 239 FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 240 13.1.3 SIEMENS HEALTHINEERS AG 242 TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 242 FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 243 13.1.4 DIASORIN S.P.A. 246 TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW 246 FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 247 13.1.5 ABBOTT LABORATORIES 248 TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW 248 FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 249 13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 251 TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 251 FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021) 252 13.1.7 SYSMEX CORPORATION 254 TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW 254 FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 255 13.1.8 DIATRON 258 TABLE 177 DIATRON: COMPANY OVERVIEW 258 FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022) 259 13.1.9 GETEIN BIOTECH, INC. 260 TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW 260 13.1.10 WERFEN 261 TABLE 179 WERFEN: COMPANY OVERVIEW 261 13.1.11 QUIDELORTHO CORPORATION 262 TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 262 FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 263 13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 265 TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW 265 *Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies. 13.2 OTHER PLAYERS 267 13.2.1 MERCK KGAA 267 13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE) 267 13.2.3 TRIVITRON HEALTHCARE 268 13.2.4 ABNOVA CORPORATION 268 13.2.5 ELABSCIENCE 269 13.2.6 MACCURA BIOTECHNOLOGY CO., LTD. 269 13.2.7 AUTOBIO DIAGNOSTICS CO., LTD 270 13.2.8 JIANGSU ZECEN BIOTECH CO., LTD 270 13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD. 271 13.2.10 DAAN GENE CO., LTD. 272 13.2.11 DYNEX TECHNOLOGIES, INC. 272 13.2.12 ZYBIO INC. 273 13.2.13 WIENER LABORATORIOS SAIC 273 13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD. 274 14 APPENDIX 275 14.1 DISCUSSION GUIDE 275 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 279 14.3 CUSTOMIZATION OPTIONS 281 14.4 RELATED REPORTS 282 14.5 AUTHOR DETAILS 283
SummaryThe chemiluminescence immunoassay market is valued at an estimated USD 13.2 billion in 2023 and is projected to reach USD 19.0 billion by 2028 at a CAGR of 7.5% during the forecast period. Diseases such as HIV/AIDS, hepatitis, respiratory infections and sexually transmitted infections, require an accurate and timely diagnosis for effective treatment and control. Chemiluminescence immunoassay plays a major role in the diagnosis and monitoring of these infectious diseases, driving the growth of the market in this area. Table of Contents1 INTRODUCTION 311.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 31 1.2.1 INCLUSIONS AND EXCLUSIONS 32 1.3 MARKET SCOPE 33 1.3.1 MARKETS COVERED 33 FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION 33 1.3.2 GEOGRAPHICAL SCOPE 33 1.3.3 YEARS CONSIDERED 34 1.4 CURRENCY CONSIDERED 34 1.5 STAKEHOLDERS 35 2 RESEARCH METHODOLOGY 36 2.1 RESEARCH APPROACH 36 FIGURE 2 RESEARCH DESIGN 36 2.1.1 SECONDARY DATA 37 2.1.1.1 Key data from secondary sources 38 2.1.2 PRIMARY DATA 38 2.1.2.1 Primary sources 39 2.1.2.2 Key data from primary sources 40 2.1.2.3 Key industry insights 41 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS 41 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 42 2.2 MARKET SIZE ESTIMATION 42 FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION 43 FIGURE 6 MARKET ESTIMATION FROM IVD MARKET 44 FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET 44 FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 45 FIGURE 9 TOP-DOWN APPROACH 45 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 47 FIGURE 10 DATA TRIANGULATION METHODOLOGY 47 2.4 MARKET SHARE ANALYSIS 48 2.5 STUDY ASSUMPTIONS 48 2.6 RESEARCH LIMITATIONS 48 2.7 RISK ASSESSMENT 49 TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET 49 2.8 GROWTH RATE ASSUMPTIONS 49 2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 49 3 EXECUTIVE SUMMARY 51 FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION) 51 FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 52 FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION) 53 FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION) 54 FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 55 FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 56 4 PREMIUM INSIGHTS 57 4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW 57 FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 57 4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022) 58 FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58 4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 59 FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 59 4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX 60 FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD 60 4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS 61 FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD 61 5 MARKET OVERVIEW 62 5.1 INTRODUCTION 62 5.2 MARKET DYNAMICS 62 FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62 5.2.1 DRIVERS 63 5.2.1.1 Increasing incidences of chronic and infectious diseases globally 63 FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL) 63 FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS) 64 5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years 64 5.2.1.3 Growth of biotechnology and biopharmaceutical industries 66 5.2.1.4 Rapid increase in geriatric population globally 67 FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 67 5.2.1.5 Shift toward personalized medicines and individualized treatment decisions 68 5.2.2 RESTRAINTS 68 5.2.2.1 High cost of chemiluminescence systems and reagents 68 5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference 68 5.2.3 OPPORTUNITIES 69 5.2.3.1 High growth prospects for players in emerging economies 69 5.2.3.2 Increasing number of collaborations and partnerships 70 5.2.4 CHALLENGES 70 5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems 70 5.2.4.2 Lack of skilled professionals and aging workforce 70 5.3 VALUE CHAIN ANALYSIS 71 FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 71 5.4 SUPPLY CHAIN ANALYSIS 72 FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES 72 5.5 PORTER’S FIVE FORCES ANALYSIS 73 TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS 73 5.5.1 DEGREE OF COMPETITION 73 5.5.2 BARGAINING POWER OF SUPPLIERS 73 5.5.3 BARGAINING POWER OF BUYERS 73 5.5.4 THREAT OF SUBSTITUTES 73 5.5.5 THREAT OF NEW ENTRANTS 74 5.6 KEY STAKEHOLDERS AND BUYING CRITERIA 74 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 74 FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 74 TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 74 5.6.2 BUYING CRITERIA 75 FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS 75 TABLE 4 KEY BUYING CRITERIA, BY END USER 75 5.7 REGULATORY LANDSCAPE 76 5.7.1 US 76 TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 76 FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES 77 5.7.2 CANADA 78 FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES 78 5.7.3 EUROPE 78 TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES 78 5.7.4 JAPAN 79 FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 79 TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS 80 TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80 5.7.5 CHINA 80 TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80 5.7.6 INDIA 81 FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES 81 5.7.7 INDONESIA 81 TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 82 5.7.8 RUSSIA 82 TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES 82 5.7.9 SAUDI ARABIA 83 TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83 5.7.10 MEXICO 83 FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 83 TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84 5.7.11 BRAZIL 84 FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 85 5.7.12 SOUTH KOREA 85 TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85 5.7.13 MIDDLE EAST 85 5.7.14 AFRICA 86 5.8 TECHNOLOGY ANALYSIS 86 TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 86 5.9 TRADE ANALYSIS 87 5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS 87 TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 87 TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 87 5.10 ECOSYSTEM MAPPING 88 FIGURE 36 ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 88 5.10.1 ROLE IN ECOSYSTEM 88 5.10.2 KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 89 5.11 PATENT ANALYSIS 89 5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 90 TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024 90 5.13 PRICING ANALYSIS 91 5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS) 91 TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD) 91 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91 6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT 92 6.1 INTRODUCTION 93 TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 93 6.2 CONSUMABLES 93 6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD 93 TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE 94 TABLE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 95 6.3 INSTRUMENTS 95 6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET 95 TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE 96 TABLE 24 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 97 7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY 98 7.1 INTRODUCTION 99 TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 99 7.2 CHEMILUMINESCENCE ENZYME 99 7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET 99 TABLE 26 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION) 100 7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY 100 7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET 100 TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION) 101 7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY 101 7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET 101 TABLE 28 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION) 102 8 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE 103 8.1 INTRODUCTION 104 TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 104 8.2 BLOOD 104 8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET 104 TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION) 105 8.3 URINE 105 8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET 105 TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION) 106 8.4 SALIVA 106 8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET 106 TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION) 107 8.5 OTHER SAMPLE TYPES 107 TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION) 108 9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION 109 9.1 INTRODUCTION 110 TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110 9.2 INFECTIOUS DISEASES 111 9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET 111 TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 111 9.3 ENDOCRINOLOGY 112 9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET 112 TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 112 9.4 ONCOLOGY 113 9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET 113 TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 114 TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 114 9.5 CARDIOLOGY 115 9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET 115 TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION) 115 9.6 ALLERGY DIAGNOSTICS 116 9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS 116 TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 116 9.7 BLOOD SCREENING 117 9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET 117 TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION) 117 9.8 AUTOIMMUNE DISORDERS 118 9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET 118 TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION) 119 9.9 BONE & MINERAL DISORDERS 119 9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 119 TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 120 9.10 TOXICOLOGY 120 9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 120 TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION) 121 9.11 NEWBORN SCREENING 121 9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL 121 TABLE 45 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION) 122 9.12 THERAPEUTIC DRUG MONITORING 122 9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET 122 TABLE 46 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION) 123 9.13 METABOLIC DISORDERS 123 9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 123 FIGURE 37 GLOBAL INCIDENCE OF DIABETES 124 TABLE 47 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 124 9.14 GASTROENTEROLOGY 125 9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET 125 TABLE 48 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION) 125 9.15 NEUROLOGY 126 9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT 126 TABLE 49 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 126 9.16 RESPIRATORY 127 9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET 127 TABLE 50 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION) 127 9.17 OTHER APPLICATIONS 128 TABLE 51 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 128 10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER 129 10.1 INTRODUCTION 130 TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 130 10.2 HOSPITALS 130 10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET 130 TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 132 10.3 CLINICAL LABORATORIES 132 10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT 132 TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 133 10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 134 10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET 134 TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 135 10.5 OTHER END USERS 135 TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 136 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION 137 11.1 INTRODUCTION 138 TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 138 11.2 NORTH AMERICA 139 FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 140 TABLE 58 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141 TABLE 59 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141 TABLE 60 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 142 TABLE 61 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 142 TABLE 62 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143 TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 144 11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA 144 11.2.2 US 145 11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period 145 TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 145 TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146 TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 146 TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147 TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 148 11.2.3 CANADA 148 11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market 148 TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES 148 TABLE 70 CANADA: MACROECONOMIC INDICATORS 150 TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150 TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 151 TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 151 TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152 TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 153 11.3 EUROPE 153 TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154 TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154 TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155 TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 155 TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 156 TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 157 11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE 157 11.3.2 GERMANY 157 11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market 157 TABLE 82 GERMANY: MACROECONOMIC INDICATORS 158 TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159 TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 159 TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 160 TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161 TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 162 11.3.3 FRANCE 162 11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market 162 TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163 TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163 TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 164 TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165 TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 166 11.3.4 UK 166 11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market 166 TABLE 93 UK: MACROECONOMIC INDICATORS 167 TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 168 TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 168 TABLE 96 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 169 TABLE 97 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170 TABLE 98 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 171 11.3.5 ITALY 171 11.3.5.1 Growing geriatric population and increasing support for research to drive market 171 TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172 TABLE 100 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172 TABLE 101 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 173 TABLE 102 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174 TABLE 103 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 175 11.3.6 SPAIN 175 11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market 175 TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176 TABLE 105 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 176 TABLE 106 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 177 TABLE 107 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178 TABLE 108 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 179 11.3.7 REST OF EUROPE 179 TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 180 TABLE 110 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180 TABLE 111 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 181 TABLE 112 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182 TABLE 113 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 183 11.4 ASIA PACIFIC 183 FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 184 TABLE 114 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 185 TABLE 115 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 185 TABLE 116 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186 TABLE 117 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 186 TABLE 118 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187 TABLE 119 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 188 11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC 188 11.4.2 JAPAN 188 11.4.2.1 Growing investments in clinical diagnostics research to drive market 188 TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 189 TABLE 121 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 190 TABLE 122 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 190 TABLE 123 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191 TABLE 124 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 192 11.4.3 CHINA 192 11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period 192 TABLE 125 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 193 TABLE 126 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 194 TABLE 127 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 194 TABLE 128 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195 TABLE 129 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 196 11.4.4 INDIA 196 11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market 196 TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 197 TABLE 131 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 198 TABLE 132 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 198 TABLE 133 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 199 TABLE 134 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 200 11.4.5 SOUTH KOREA 200 11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market 200 TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 201 TABLE 136 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 201 TABLE 137 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 202 TABLE 138 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203 TABLE 139 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 204 11.4.6 REST OF ASIA PACIFIC 204 TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205 TABLE 141 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 206 TABLE 142 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 206 TABLE 143 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207 TABLE 144 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 208 11.5 REST OF THE WORLD 208 TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 208 TABLE 146 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 209 TABLE 147 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 209 TABLE 148 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 210 TABLE 149 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211 TABLE 150 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 212 11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD 212 11.5.2 LATIN AMERICA 212 11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market 212 TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 213 TABLE 152 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 214 TABLE 153 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 214 TABLE 154 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 215 TABLE 155 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 216 11.5.3 MIDDLE EAST & AFRICA 216 11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market 216 TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 217 TABLE 157 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 217 TABLE 158 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 218 TABLE 159 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 219 TABLE 160 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 220 12 COMPETITIVE LANDSCAPE 221 12.1 OVERVIEW 221 12.2 STRATEGIES ADOPTED BY KEY PLAYERS 221 TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS 222 12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 223 FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 223 12.4 MARKET SHARE ANALYSIS 224 TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION 224 FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022) 225 12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 226 12.5.1 STARS 226 12.5.2 EMERGING LEADERS 226 12.5.3 PERVASIVE PLAYERS 226 12.5.4 PARTICIPANTS 226 FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS 227 12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 228 12.6.1 PROGRESSIVE COMPANIES 228 12.6.2 STARTING BLOCKS 228 12.6.3 RESPONSIVE COMPANIES 228 12.6.4 DYNAMIC COMPANIES 228 FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES 229 12.7 COMPETITIVE BENCHMARKING 230 TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES 230 12.8 COMPANY FOOTPRINT ANALYSIS 231 TABLE 164 OVERALL COMPANY FOOTPRINT 231 TABLE 165 COMPANY PRODUCT FOOTPRINT 231 TABLE 166 COMPANY REGIONAL FOOTPRINT 232 12.9 COMPETITIVE SCENARIO 232 12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS 232 TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023 232 12.9.2 KEY DEALS 234 TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020–2023 234 12.9.3 OTHER KEY DEVELOPMENTS 234 TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023 234 13 COMPANY PROFILES 236 13.1 KEY PLAYERS 236 (Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)* 13.1.1 F. HOFFMANN-LA ROCHE LTD. 236 TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 236 FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 237 13.1.2 DANAHER CORPORATION 239 TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW 239 FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 240 13.1.3 SIEMENS HEALTHINEERS AG 242 TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 242 FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 243 13.1.4 DIASORIN S.P.A. 246 TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW 246 FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 247 13.1.5 ABBOTT LABORATORIES 248 TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW 248 FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 249 13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 251 TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 251 FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021) 252 13.1.7 SYSMEX CORPORATION 254 TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW 254 FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 255 13.1.8 DIATRON 258 TABLE 177 DIATRON: COMPANY OVERVIEW 258 FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022) 259 13.1.9 GETEIN BIOTECH, INC. 260 TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW 260 13.1.10 WERFEN 261 TABLE 179 WERFEN: COMPANY OVERVIEW 261 13.1.11 QUIDELORTHO CORPORATION 262 TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 262 FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 263 13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 265 TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW 265 *Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies. 13.2 OTHER PLAYERS 267 13.2.1 MERCK KGAA 267 13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE) 267 13.2.3 TRIVITRON HEALTHCARE 268 13.2.4 ABNOVA CORPORATION 268 13.2.5 ELABSCIENCE 269 13.2.6 MACCURA BIOTECHNOLOGY CO., LTD. 269 13.2.7 AUTOBIO DIAGNOSTICS CO., LTD 270 13.2.8 JIANGSU ZECEN BIOTECH CO., LTD 270 13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD. 271 13.2.10 DAAN GENE CO., LTD. 272 13.2.11 DYNEX TECHNOLOGIES, INC. 272 13.2.12 ZYBIO INC. 273 13.2.13 WIENER LABORATORIOS SAIC 273 13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD. 274 14 APPENDIX 275 14.1 DISCUSSION GUIDE 275 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 279 14.3 CUSTOMIZATION OPTIONS 281 14.4 RELATED REPORTS 282 14.5 AUTHOR DETAILS 283
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
MarketsandMarkets社のMedical Devices分野での最新刊レポート
本レポートと同じKEY WORD(blood urine)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |